Clinical data | |
---|---|
Other names | DWP16001 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H27ClO6 |
Molar mass | 446.92 g·mol−1 |
3D model (JSmol) | |
| |
|
Enavogliflozin (DWP16001) is an experimental selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity.[1][2][3][4][5]